Drug Trial Radar · NCT03170960
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
914
Actual
Start
Sep 5, 2017
Primary completion
Feb 21, 2023
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- ExelixisIndustry
- Sponsor type
- Industry
- First posted
- May 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.
Conditions
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Non-Small Cell Lung Cancer
- Castration-resistant Prostate Cancer
- Triple Negative Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- Hepatocellular Carcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Colorectal Cancer
- Head and Neck Cancer
- Differentiated Thyroid Cancer
- Lower Esophageal Cancer
Interventions
cabozantinibDrug
Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
atezolizumabDrug
Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
cabozantinibDrug
Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
cabozantinibDrug
Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: MTD/Recommended DoseTime frame: Up to Day 21
- Dose Expansion: ORRTime frame: Up to a maximum of 59 months
Locations
124 sites in 9 countries. Site status is shown where the registry gives one.
Exelixis Clinical Site #53
Gilbert, Arizona
Exelixis Clinical Site #18
Phoenix, Arizona
Exelixis Clinical Site #1
Duarte, California
Exelixis Clinical Site #20
La Jolla, California
Exelixis Clinical Site #46
Los Angeles, California
Exelixis Clinical Site #51
Newport Beach, California
Exelixis Clinical Site #62
Santa Monica, California
Exelixis Clinical Site #21
Stanford, California
Exelixis Clinical Site #34
Denver, Colorado
Exelixis Clinical Site #50
Denver, Colorado
Exelixis Clinical Site #42
New Haven, Connecticut
Exelixis Clinical Site #48
Washington D.C., District of Columbia
Exelixis Clinical Site #16
Jacksonville, Florida
Exelixis Clinical Site #76
Tampa, Florida
Exelixis Clinical Site #60
Atlanta, Georgia
Exelixis Clinical Site #79
Atlanta, Georgia
Exelixis Clinical Site #32
Harvey, Illinois
Exelixis Clinical Site #23
Fairway, Kansas
Exelixis Clinical Site #57
Lexington, Kentucky
Exelixis Clinical Site #24
New Orleans, Louisiana
Exelixis Clinical Site #10
Boston, Massachusetts
Exelixis Clinical Site #3
Detroit, Michigan
Exelixis Clinical Site #17
Rochester, Minnesota
Exelixis Clinical Site #65
Bolivar, Missouri
Exelixis Clinical Site #43
Kansas City, Missouri
Exelixis Clinical Site #35
Omaha, Nebraska
Exelixis Clinical Site #59
Omaha, Nebraska
Exelixis Clinical Site #61
Las Vegas, Nevada
Exelixis Clinical Site #38
Camden, New Jersey
Exelixis Clinical Site #27
East Brunswick, New Jersey
Exelixis Clinical Site #31
New Brunswick, New Jersey
Exelixis Clinical Site #40
East Setauket, New York
Exelixis Clinical Site #11
New York, New York
Exelixis Clinical Site #37
The Bronx, New York
Exelixis Clinical Site #67
Cleveland, Ohio
Exelixis Clinical Site #49
Columbus, Ohio
Exelixis Clinical Site #64
Kettering, Ohio
Exelixis Clinical Site #71
Oklahoma City, Oklahoma
Exelixis Clinical Site #6
Oklahoma City, Oklahoma
Exelixis Clinical Site #102
Portland, Oregon
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.